Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care
The analysis of circulating tumor DNA (ctDNA) is at the threshold of implementation into standard care for colorectal cancer (CRC) patients. However, data about the clinical utility of liquid profiling (LP), its acceptance by clinicians, and its integration into clinical workflows in real‐world sett...
Main Authors: | Maren Hedtke, Rodrigo Pessoa Rejas, Matthias F. Froelich, Volker Ast, Angelika Duda, Laura Mirbach, Victor Costina, Uwe M. Martens, Ralf‐Dieter Hofheinz, Michael Neumaier, Verena Haselmann |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-05-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.13156 |
Similar Items
-
Status of liquid profiling in precision oncology – the need for integrative diagnostics for successful implementation into standard care
by: Froelich Matthias F., et al.
Published: (2022-08-01) -
Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges
by: Ander Saenz-Antoñanzas, et al.
Published: (2019-07-01) -
Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
by: Lionel Larribère, et al.
Published: (2021-11-01) -
Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
by: Jonathan Dao, et al.
Published: (2023-08-01) -
The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma—Literature Review
by: Agnieszka Kopystecka, et al.
Published: (2023-05-01)